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INTRODUCTION 
 
        In 1000 BC life expectancy was only 17 years and by the time of 100 BC in 
the time of Julius Caesar, it had reached 25 years. In 2000 AD the average life 
expectancy was 79.7 years for women and 74.3 for men (Centers for Disease 
Control and Prevention 2004). Osteoporosis the most prevalent and a major 
global public health problem affecting elderly women 4 times more commonly 
than men. (National osteoporosis foundation 2003) Because of this demographic 
change the number of hip fractures increase approximately six fold increasing the 
morbidity in the postmenopausal group. (Cooper et al) [1] 
 
        Osteoporosis is highly prevalent in India, 4 to 6 million people are affected, 
it is projected  that by the year 2030 the proportion of postmenopausal women 
will be 2nd highest next to china and the burden of osteoporosis in India will also 
be very high (Gupta et al) [2] 
 
Osteoporosis is characterized by low bone mass and micro architectural 
deterioration of Bone tissue leading to enhanced bone fragility consequently 
increased risk of fractures even with little or no trauma. Post menopausal status 
directly attributes to osteoporosis due to hormonal deficiency and contributes to 
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significant morbidity, mortality, reduction in quality of life, and increasing health 
care costs. Various drugs used are as follows: 
 
• Sex hormones 
• Bisphosphonates 
• Calcitonin 
• Calcium and vitamin D 
• Tibolone 
• Teriparatide 
• Flouride 
• Statins 
• Thiazides 
• SERMS 
 
                Raloxifene is a selective estrogen receptor modulator used in the 
prevention and management of postmenopausal osteoporosis. To date there has 
been few prospective trials and several randomized control trials since 1997 
comparing Raloxifene with various other standard therapies. This prospective 
study was undertaken to assess the efficacy of Raloxifene in the treatment of 
postmenopausal osteoporosis. 
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REVIEW OF LITERATURE 
 
MENOPAUSE AND OSTEOPOROSIS 
 
MENOPAUSE: 
         Menopause is defined as the permanent cessation of menstruation resulting 
from loss of ovarian follicular activity (WHO Scientific group 1983). There 
should be amenorrhea for at least 6 months in a women aged about 45 -50 years 
without any associated clinical manifestation other than those connected with low 
endogenous estrogen.  
 
Usually occurs between 45 and 52. The average age being 48 (McKinley et al) [3]. 
 
POST MENOPAUSE: 
              A woman who has ceased to menstruate for at least 6 months to 1 year 
after the onset of menopause.  Epidemiological studies, have found the mean age 
of menopause to be around 51 yr in Caucasians and Asians. Boulet et al[4] 
 
Menopause – An overview 
 
The life cycle of a woman can be divided into three sub cycles: 
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• Reproductive life 
• Perimenopausal period (premenopausal symptoms accompanied by 
amenorrhea lasting up to one year) 
• Post menopause (confirmed menopause with no menstruation for at least 
one year). 
 
 
Cross-sectional and longitudinal studies have shown the age of menopause to be 
between 49 and 51 years in Caucasian women; around 49 years in US black and 
South African women; and 45 years on average in India [41] Boulet et al. 
Differences may be due to such factors as socioeconomics, nutrition, health 
status, health habits, marital status and employment status. Health habits, such as 
nicotine and CO2 intake from smoking, can hasten the onset of menopause by 
adversely affecting ovarian circulation, reducing hemoglobin and destroying 
undeveloped ova. 
 
Type of onset of menopause: 
 
  Gradual 
• Gradual decrease in the amount of flow. 
• Interval between the consecutive cycles increases with time. 
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  Abrupt 
• Sudden without any warning. 
 
IMPACT OF POST MENOPAUSAL ESTROGEN DEPRIVATION: 
 
• Vasomotor disturbances 
• Atrophic changes 
• Cognition and Alzheimer’s disease 
• Cardiovascular disease 
• Osteoporosis 
Most women experience some effects of estrogen deficiency during menopause. 
Effects range from short term discomfort to long term changes that have profound 
effect on women’s health. 
 
IMPACT OF MENOPAUSE ON OSTEOPOROSIS: 
Bones are comprised of two major ingredients: 
I  Minerals (including calcium and phosphorous)  
II Bone cells (consisting of osteoblasts and osteoclasts).  
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Large amounts of calcium and other minerals are laid down during  teenage years, 
in preparation for adult growth. In order to stay strong and healthy,bones 
constantly regenerate themselves. The bone cells work together to reabsorb and 
then regenerate our bones. Peak bone mass is reached between the ages of 20 and 
30. 
After the age of 30, bones do not regenerate in the same way. Most women and 
men lose about 1% of their bone mass throughout a year - this is part of the 
natural aging process.Since Estrogen keeps the osteoclasts in check, allowing the 
osteoblasts to build more bone,during menopause women begin to lose much 
more bone than their male counterparts as much as between 2% and 7% of the 
bone mass every year making the bones susceptible to  fractures. Bugliosi R, et al 
[5] and Cummings et al [6]. 
The largest amount of bone loss occurs in the first five years following 
menopause. Leo Vankrieken [7]. It is important to conserve bone mass to avoid 
debilitating fractures of the hip, spine, and wrist. Osteoporosis is of particular 
concern as it is a silent epidemic can seriously affect  health and longevity.  
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OSTEOPOROSIS 
A clinical definition of osteoporosis was developed in 2001 by the NIH 
Consensus Development Panel on Osteoporosis. It stated: “Osteoporosis is 
defined as a skeletal disorder characterized by compromised bone strength 
predisposing a person to an increased risk of fracture”. 
The WHO Working Group defines osteoporosis according to measurements of 
bone mineral density (BMD) using dual-energy X-ray absorptiometry (DEXA). 
Thus osteoporosis is defined as a bone density T scores at or below 2.5 standard 
deviations (T score) below normal peak values for young adults. 
 
PATHOPHYSIOLOGY OF OSTEOPOROSIS: 
A deficiency in estrogen is associated with greater responsiveness of the bone to 
Parathyroid hormone. Thus, for any given level of Para thyroid hormone there is 
more calcium removed from the bone raising serum ca which in turn lowers PTH 
and decreases vitamin D and intestinal absorption of calcium. Osteoporosis 
develops insidiously. Symptoms typically do not appear until advanced stages of 
bone resorption have already been reached. Risk of fracture from Osteoporosis 
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will depend on bone mass at the time of menopause and rate of bone loss 
following menopause. (Riis BJ et al) [8] 
Most of the bone mass in the hip and the vertebral body is accumulated by the age 
of 18 only a slight gain continues thereafter that ceases around 30 and this 
declines by 0.7 % every year. For the first 20 years following menopause 50% 
reduction takes place in trabecular bone and 30% in cortical bone. High rate of 
bone loss after menopause (the fast looser) is highly predictive of an increased 
risk of fracture. These fast losers probably reflect the lower endogenous levels of 
estrogen. (Sabatier et al) [9] 
RISK FACTORS FOR OSTEOPOROSIS 
• Female sex 
• Age > 70 years 
• Caucasian or Asian race 
• Early onset of menopause 
• Longer postmenopausal interval 
• Inactivity, especially lack of weight bearing exercise 
Osteoporosis can be classified as primary or secondary. Primary osteoporosis is 
the form seen in older persons and women past menopause in which bone loss is 
 14 of 78 
accelerated over that predicted for age and sex. Secondary osteoporosis results 
from a variety of identifiable conditions that may include: 
• Metabolic bone disease, such as hyperparathyroidism 
• Neoplasia, as with multiple myeloma or metastatic carcinoma 
• Malnutrition 
• Drug therapy, as with corticosteroids 
• Prolonged immobilization 
• Weightlessness with space travel 
• Anorexia nervosa, 
• Type I diabetes 
Modifiable risk factors that may potentiate osteoporosis include:  
• Smoking 
• Alcohol abuse 
• Excessive caffeine consumption 
• Excessive dietary protein consumption 
• Lack of dietary calcium 
• Lack of sunlight exposure (to generate endogenous vitamin D) 
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SIGNS AND SYMPTOMS OF OSTEOPOROSIS: 
• Back pain  
• Decreased height and mobility 
• Fractures of the vertebral body, humerus, and upper femur, distal forearm 
and ribs.  
• Pain due to fractures. 
 
DIAGNOSIS 
Diagnosis of osteoporosis is made by three methods: 
1. Radiographic measurement of bone density 
2. Laboratory biochemical markers 
3. Bone biopsy with pathologic assessment 
Of these three the best is radiographic bone density  
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BONE MINERAL DENSITY: 
Bone mineral density is defined as the amount of calcium and other bone minerals 
in grams per square centimeter — collectively known as bone mineral content  
packed into a segment of bone. Mineral content and the density   of the bones are 
directly proportional 
Bone mineral density (BMD) test measures the mineral density in the bones using 
computed tomography (CT scan), or ultrasound. 
 
.  
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Bone mass increases in both sexes through the growth stage. After puberty, men 
develop approximately twice as much bone mass as women, both achieve peak 
bone mass in the third decade of life. During this time, bone formation and 
resorption are at equilibrium. Depending on an individual’s bone mass at age 25, 
there is a greater or lesser risk for osteoporosis over time. 
 
Although bone mass declines with age in both men and women, decreases in the 
production of estrogen at menopause trigger a more rapid rate of bone mass loss 
in some women. On average, women have less bone mass than men and, after 
menopause, they lose bone mass at a more rapid rate. Ross et al [10]  
 
The rate of decline in BMD at menopause differs widely among women, 
exceeding 5 percent per year in some. Such individuals have been called “rapid 
bone losers.” Riggs et al [11]. Since women reach disproportionately low bone 
mass levels, osteoporosis is predominantly a disease of post menopausal women. 
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METHODS TO ASSESS BONE MINERAL DENSITY: 
 
Standard X rays: They do not provide an early assessment of fracture risk 30% 
to 40% of the bone must be lost before radiological changes become apparent. 
 
Ultrasonography: This method is effective rapid, painless, and does not use 
potentially harmful radiation like X-rays and low cost for bone mass assessment. 
(Gregg et al) [12]. 
 
Ultra sound measurements of calcaneum have been reported to be as accurate as 
femoral neck measurements by DEXA in predicting hip fractures (Nejh CF et al 
[43]). Ultrasound is generally used as an initial screening test. If results from an 
ultrasound test indicate that bone density is low, DEXA is recommended to 
confirm the results. One disadvantage of ultrasound is it cannot measure the 
density of the bones most likely to fracture (the hip and spine) from osteoporosis. 
Also, ultrasound has limited usefulness (compared to DEXA) for monitoring and 
comparing the effect of medications used to treat osteoporosis 
 
Single Photon absorptiometry: It uses 125 I as a source of energy more recently 
by minature X ray tubes. Bone density of radius and calcaneum are measured and 
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are relatively inexpensive, these measurements correlate with vertebral bone 
density and predict future fracture risk (Johnston et al [13]). 
 
Dual photon absorptiometry (DPA). DPA uses a radioactive substance to 
produce radiation. It can measure BMD in hip and spine. DPA also uses very low 
doses of radiation but has a slower scan time than the other methods. 
 
Quantitative computed tomography (QCT). Quantitative computed 
tomography (QCT) is a type of CT scan that measures the density of a bone in the 
spine. A form of QCT called peripheral QCT (pQCT) measures the density of 
bones in limbs, such as wrist. QCT is not usually recommended because it is 
expensive, uses higher radiation doses, and is less accurate than DEXA, P-DEXA, 
or DPA. 
Peripheral dual-energy X-ray absorptiometry (P-DEXA). P-DEXA is a 
modification of the DEXA technique. It measures the density of bones in limbs, 
such as wrist—it cannot measure the density of the bones most likely to fracture 
(the hip and spine). If hip or spinal bone density is measured, peripheral 
measurement is not needed. P-DEXA machines are portable units that can be used 
in a doctor's office. P-DEXA also uses very low doses of radiation, and the results 
are faster than conventional DEXA measurements. P-DEXA has limited 
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usefulness (compared to DEXA) for monitoring the effect of medication used to 
treat osteoporosis. 
QUANTITATIVE COMPUTED TOMOGRAPHY DUAL-ENERGY X-RAY 
ABSORPTIOMETRY (DEXA). 
 
Dual-energy x-ray absorptiometry (DXA) is considered the gold standard because 
it is the most extensively validated test against fracture outcomes DEXA uses two 
different X-ray beams to estimate bone density in  spine and hip. .It provides good 
precision for osteoporotic fractures and the radiation dose is much less than for a 
standard chest X ray. Scans by Dexa can measure total body calcium lean body 
mass and fat mass.  
DEXA can measure as little as 2% of bone loss per year. It is fast and uses very 
low doses of radiation but is more expensive than ultrasound testing. The lumbar 
region from L1 to L4 is specifically very sensitive to the osteoporotic changes due 
to estrogen deficiency. 
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T  Score --- Standard deviations between patient and average peak young adult 
bone mass. The more negative, the greater the risk of fracture. 
 
Z  Score --- Standard deviations between patient and average bone mass for same 
age and weight. A Z score lower than -2.0 (2.5 % of normal population of same 
age) requires diagnostic evaluation for causes other than post menopausal bone 
mass. 
 
DEFINITION BASED ON BONE MINERAL DENSITY (Kanis et al) [14] 
 
NORMAL --- 0 TO -1 S.D from the reference standard (84% of the population) 
OSTEOPENIA --- -1 TO -2.5 S.D 
OSTEOPOROSIS --- T score less than - 2.5 
The clinical relevance of bone density measurement in post menopausal women is 
estimated by using T score. For younger women is estimated by Z score. 
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World Health Organization's definitions of osteoporosis based on bone mineral 
density T-scores. 
Bone mineral density  
  T-score  
Normal: 2.5 to 1 below the young adult reference range (2.5 to –1) 
Low bone mass 
(osteopenia):  
1 to 2.5 SDs below the young adult reference range (–1 to –2.5) 
Osteoporosis: 2.5 or more SDs below the young adult reference range (–2.5 or 
less) 
Severe osteoporosis: 2.5 or more SDs below the young adult reference range (–2.5 or 
less) and the presence of one or more bone fractures 
Every change of 1 SD means a twofold increase in the risk of fracture at that site. 
Decision for clinical treatment is based  on lowest T score at particular site rather 
than the highest average score as this is associated with increased fracture risk 
Low BMD values may be caused by other disorders, such as hyperthyroidism, 
hyperparathyroidism, multiple myeloma, Cushing's syndrome, ankylosing 
spondylitis, rickets, premature menopause, or a vitamin D deficiency. 
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Factors that interfere with the accuracy of the results: 
• Correct positioning, which is important for an accurate bone mineral 
density (BMD) measurement. 
• Previous bone fracture. This can cause falsely high BMD values. 
• Metal objects, such as buttons, buckles, jewelry, or metal implants from 
hip replacement surgery or hip fracture. 
• Barium tests within 14 days of the BMD test. 
The DEXA machine sends a thin, invisible beam of low-dose x-rays with two 
distinct energy peaks through the bones being examined. One peak is absorbed 
mainly by soft tissue and the other by bone. The soft tissue amount can be 
subtracted from the total and what remains is a patient's bone mineral density. 
     The effective radiation dose from this procedure is about 0.01 mSv, despite its 
effectiveness as a method of measuring bone density, DEXA is of limited use in 
people with a spinal deformity or those who have had previous spinal surgery. 
The presence of vertebral compression fractures or osteoarthritis may interfere 
with the accuracy of the test 
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DRUGS USED IN OSTEOPOROSIS: 
HORMONES: Treatment with conjugated estrogens effectively reduces the 
osteoporotic fractures but long term estrogen use is necessary to reduce the risk 
after 75 years.  
BISPHOSPHONATES: Bisphosphonates enhance the osteoclast apoptosis and 
inhibit bone resorption, bind to bone mineral and exert their actions .they are 
taken half an hour prior to food.  
CALCITONIN: It helps in reducing bone resorption; recombinant salmon 
calcitonin is more potent. In a randomized 5 year trial calcitonin treatment was 
less effective than estrogen, bisphosphonates and Raloxifene (Chesnut et al) [15]. 
FLOURIDE: It is a potent stimulator of bone formation. Slow release sodium 
fluoride with calcium reduces the vertebral fracture risk. Treatment is 
recommended no longer than 4 years due to toxic accumulation of the drug [16]. 
Pak et al 
TIBOLONE: It is structurally related to 19-nor testerone progestins. Prevents 
bone loss effectively as estrogens. Its ultimate effect on fractures and bone 
mineral density awaits more clinical trials. Studd et al [17] 
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TERIPARATIDE: It is a recombinant human amino acid fragment of 
parathyroid hormone. Given once daily subcutaneous dose improves the bone 
density (cosman et al). Because of the expense and difficulty in self 
administration used only in severe osteoporosis. 
GROWTH HORMONE: Growth hormone improves the bone density 
significantly .its expense and the high incidence of unpleasant side effects makes 
it a poor option. (Holloway et al) 
 
RALOXIFENE 
SERMS are group of drugs that activate the estrogen receptors, but have different 
effects on different tissues. Raloxifene is the first of a benzothiophene series of 
anti-estrogens to be labeled a SERM. (Droloxifine, idoxifene and toremifene are 
similar SERM agents, but they are still considered experimental.).  
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It has been studied in placebo-controlled trials with durations up to 8 years.  
In December 1997, the U.S. Food and Drug Administration (FDA) labeled 
Raloxifene for the prevention of osteoporosis. 
CHEMISTRY: 
Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4S•HCl, 
which corresponds to a molecular weight of 510.05 g/mol. Raloxifene HCl is an 
off-white to pale-yellow solid that is very slightly soluble in water. 
Systematic (IUPAC) name [6-hydroxy-2-(4-hydroxyphenyl) - benzothiophen-3-
yl] - [4-[2-(1-piperidyl) ethoxy] phenyl] –methanone. C28H27NO4S  
MECHANISM OF ACTION: 
SERMs are capable of inducing conformational changes in the estrogen receptor 
which are of two kinds; they mediate specific pharmacologic activity involving 
multiple molecular pathways that may result in gene expression of ligand-, tissue- 
and/or gene-specific receptors. (Mitlak et al) [18]  through their unique agonist or 
antagonist properties.  
Raloxifene has the ability to bind to and activate the estrogen receptor alpha more 
than beta while exhibiting tissue-specific effects distinct from estradiol. (Yang et 
al) [19]. Some of these will act like estrogen; others will inhibit the actions of 
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estrogen.  (Stabilize bone mass, improve lipid profile, reduce hot flashes) but do 
not act like estrogen in undesirable ways (cause breast cancer, stimulate the 
endometrium).   
 
ROUTE OF ADMINISTRATION: Oral. 
 
PHARMACOKINETICS [25]  
Raloxifene is rapidly absorbed after oral administration, and its absolute 
bioavailability is 2 percent. The drug can be administered without regard to foods, 
consumption of high-fat meals may increase its systemic bioavailability 
Raloxifene undergoes extensive systemic biotransformation, but it is not 
metabolised by the cytochrome P450 pathway.  
Raloxifene has a plasma elimination half-life of 27 hours. This has attributed to 
the drug's reversible systemic metabolism and significant enterohepatic cycling. 
[20] 
Although Raloxifene and its metabolites are highly bound to plasma proteins 
(more than 95 percent), Raloxifene does not interact with the binding of other 
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highly protein-bound drugs. Raloxifene is eliminated primarily in the feces and 
only negligible amounts appear in the urine.  
INDICATION 
In the treatment and prevention of osteoporosis in postmenopausal women. 
 
CONTRAINDICATION 
• Lactating women or women who are or may become pregnant  
• Active  or past history of venous thromboembolic events (deep vein 
thrombosis,  
• pulmonary embolism, and retinal vein thrombosis ) 
• Hypersensitive to Raloxifene. 
ADVERSE REACTIONS 
Common adverse events to be drug-related are hot flashes (Weerapan et al) [21] 
and leg cramps. 
Raloxifene may infrequently cause serious thrombosis. (Miltak et al) [18]  
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Effects on Bone 
Raloxifene decreased bone turnover markers to levels similar to those found in 
pre-menopausal women. It increases the mean bone mineral density in the spines, 
hip and femoral neck.  
Effects on Lipids 
Raloxifene  produces a reduction in total and low-density lipoprotein cholesterol 
concentrations, but high-density lipoprotein cholesterol and triglyceride 
concentrations do not increase.(Weerapa et al) [21]  and Yang et al [19] 
Effects on the Uterus 
Raloxifene lacks proliferative effects on endometrial tissue. It has minimal effects 
on the uterus and causes no significant changes in the histological appearance of 
the endometrium. (Huster et al) [22]. It neither affects the endometrial thickness 
nor the uterine volume) Boss et al [23]. 
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VARIOUS STUDIES ON RALOXIFENE 
 
The introduction of Raloxifene for the treatment of postmenopausal osteoporosis 
has decreased the fracture rates and improved the well being in the 
postmenopausal group (MORE STUDY) 
 
An estimate of 61 million people in India   are reported to be affected by 
osteoporosis (Joshi VR et al) [24] 
The MORE study  by Ettinger et al [25] shows that three years of Raloxifene 
treatment preserves bone density, reduces bone turnover, and reduces the rate of 
vertebral fracture in postmenopausal women with osteoporosis. (CORE). [26] 
The FDA labeling of Raloxifene for the prevention of osteoporosis in 
postmenopausal women was originally based on the results of three large 
randomized, placebo-controlled trials conducted over a 24-month period. (Mitlak 
et al) [18].   
 
A study conduced by Pierre Delmas et al [27] on effects of Raloxifene on Bone 
Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in 
Postmenopausal Women, concluded that Raloxifene increases the bone mineral 
 32 of 78 
density, and decreases the total and low density lipoproteins and no effects on 
uterine endometrium. 
 
A double blinded randomized parallel trial comparing Raloxifene with HRT by 
Brian W. Walsh et al [28] concluded that Raloxifene favorably alters biochemical 
markers of cardiovascular risk by decreasing LDL-C, fibrinogen, and lipoprotein 
(a), and by increasing HDL2-C without raising triglycerides. 
 
 
A randomized, double-blind, placebo-controlled trial with Raloxifene by 
Annie W. C. Kung et al [29] in postmenopausal Asian women concluded to 
have beneficial effects in terms of bone mineral density and lipid profile. 
 
A phase II clinical trial conducted by J. Eng-Wong et al [30] on Effect of 
Raloxifene on bone mineral density in pre-menopausal women at increased risk 
of breast cancer revealed a decrease in the bone mineral density. 
 
Three-year data from 2 double-blind, randomized, placebo-controlled trial by 
Johnston CC Jr et al [31] on  Long-term effects of Raloxifene on bone mineral 
density, bone turnover, and serum lipid levels in early postmenopausal women 
concluded  that Raloxifene preserves BMD at important skeletal sites, lowers 
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serum low-density lipoprotein cholesterol levels, and has a tolerability profile 
comparable to placebo. These results indicate a favorable benefit-risk profile of 
Raloxifene for long-term use in healthy postmenopausal women.  
 
Three-Year Data From 2 Double-blind, Randomized, Placebo-Controlled Trials 
by C. Conrad Johnston, et al [32] on Long-term Effects of Raloxifene on Bone 
Mineral Density, Bone Turnover, and Serum Lipid Levels in Early 
Postmenopausal Women shows that Raloxifene preserves BMD in important 
skeletal sites  and has good tolerability profile comparable to placebo. 
 
Effects of Raloxifene on Markers of Bone Turnover in Older Women Living in 
Long-Term Care Facilities, a clinical intervention by Helga Hansdóttir et al, [33] 
were that Raloxifene reduces bone turnover in elderly women living in long-term 
care facilities. The effect of Raloxifene on bone turnover was comparable with 
that seen in younger postmenopausal women. 
 
Draper et al [34] studied the effects of Raloxifene on biochemical markers of bone 
turnover. In this randomized, double-blind, multicenter trial, authors concluded 
that Raloxifene appears to exert an estrogen-like positive effect on the markers of 
bone turnover. 
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A comparative study by Christoph A Meier et al [35] comparing Raloxifene with 
alendronate (bisphosphonate) shows, Although alendronate has been proven 
effective in preventing vertebral fractures in women with established 
osteoporosis, it is cumbersome to ingest (the drug needs to be taken on an empty 
stomach, and requires remaining in an upright position for 30min) and lacks the 
cardio protective effects of estrogen. The benefits of Raloxifene (lipid lowering, 
antiestrogenic action on breast and uterus) beyond its action on bone resorption 
are very useful. 
 
Meta-Analysis of Raloxifene by Ann Cranney et al [36] for the Prevention and 
Treatment of Postmenopausal Osteoporosis, data shows an increase in bone 
density, and the effect increases over 2 yr. The data suggest a positive impact of 
Raloxifene on vertebral fractures with little effect of Raloxifene on no vertebral 
fractures. 
 
A comparative study by Robert S. Weinstein [37] on the Effects of Raloxifene, 
hormone replacement therapy, and placebo on bone turnover in postmenopausal 
women supports the hypothesis that Raloxifene preserves bone mass by reducing 
the elevated bone turnover found in postmenopausal women receiving placebo, 
by mechanisms similar to those operative in postmenopausal women receiving 
HRT. 
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A study conducted on Clinical effects of Raloxifene hydrochloride in women by 
Khovidhunkit W et al [38] Raloxifene has been shown to have beneficial effects 
in selected organs in postmenopausal women. Although estrogen remains the 
drug of choice for hormonal therapy in most postmenopausal women, Raloxifene 
may be an alternative in certain groups of women at risk for osteoporosis. 
 
Liu Jian et al [39] in a randomized controlled study with Chinese population 
determined a positive effect of Raloxifene on bone mineral density of the hip and 
a decrease in the biochemical markers of bone metabolism. A decrease in total 
cholesterol and LDL with no change in HDL and triglycerides. 
 
H mori et al [40] in a study on effects of Raloxifene in Japanese population 
revealed an increase in lumbar BMD and favourable effects in the biochemical 
markers of bone turn over and lipid profile. There were no reported 
thromboembolic events. 
 
 
Sambrook PN et al [41] in a study on combination therapy of Alendronate and 
Raloxifene in post menopausal osteoporosis proved to have additive effects on 
bone mineral density than either treatment alone. 
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A study conducted by L J Black et al [42] on the effects of Raloxifene suggests 
that it prevents bone loss and reduces serum cholesterol without causing uterine 
hypertrophy in ovariectomized rats. 
 
AIM OF THE STUDY 
The aim of this study was to determine the efficacy of Raloxifene in 
postmenopausal women by comparing the pretreatment and post treatment bone 
mineral density levels. 
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SUBJECT AND METHODS 
This was a prospective randomised placebo control study conducted at Govt. 
Kasthurba Gandhi Hospital, Chennai at the department of Obstetrics and 
Gynecology. This study comprised of study subject (n=50) postmenopausal 
women attending gynaec op for other problems from September 2004 to 
September 2006. The study was approved by the hospital ethical committee. The 
BMD studies were done at SMS Medica-Chennai osteoporosis detection centre, 
Nungambakkam Chennai.  
INCLUSION CRITERIA: 
• Women who attained spontaneous menopause 
• The duration of menopause being minimum of two years. 
• Not on any drugs like hormone replacement, Vit D, Ca supplementation. 
• No history of any vertebral compression fractures 
• No history any spinal deformity or spinal surgery. 
• No history of osteoarthritis 
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EXCLUSION CRITERIA: 
• Patients with menopausal symptoms. 
• Patients with history  of postmenopausal bleeding 
• Patients on chronic medication. 
• Patients who had hysterectomy or premature menopause. 
• Patients having active rheumatoid arthritis, gastrointestinal, liver, 
metabolic, and Neoplastic or endocrinological disease. 
• History of recurrent vascular thrombosis 
• Family history of any breast or genital malignancies. 
• Hyperparathyroidism, Pagets disease, Renal osteodystrophy 
• History of treatment with bisphosphonates, sodiumflouride, calcitonin, 
estroprogestins, 
• anabolic steroids, cortcosteroids, Calcium or vitamin D supplementation 
• Smokers or alcoholics 
 
METHODS: 
The women so selected based on the inclusion and exclusion criteria were 
explained about the study and consent was obtained. Detailed menstrual, 
obstetric, drug intake history was taken. Each subject underwent general physical, 
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systemic abdominal examination. They were randomly assigned to the study and 
control groups and were subjected to DEXA scan. On the day of scan subjects 
were asked to eat normally. To avoid calcium supplements for at least 24 hours 
before the scan. 
They were requested to wear loose, comfortable clothing, avoiding garments that 
have zippers, belts   or buttons made of metal and were asked to remove jewelry, 
eye glasses and any metal objects or clothing that might interfere with the images. 
Following DEXA, those assigned to the study group were given   60 mg 
Raloxifene orally for one year. For the randomly assigned matched control group, 
similarly shaped inert capsules were given for the same duration. 
PROCEDURE: 
Scan mode—fast performance 
Model—Hologic QDR-4000(S/N 55504) 
To assess the spine, the patient's legs are supported on a padded box to flatten the 
pelvis and lumbar spine.  
The detector is slowly passed over the area, generating images on a computer 
monitor. The patient was asked to hold her breath for a few seconds while the 
picture is taken to reduce the possibility of a blurred image. 
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All the women were reviewed monthly to detect any adverse effects, and their 
adherence to the treatment protocol. The same patients were subjected to DEXA 
scan at the same site after one year. The patients, who failed to turn up for any 
visit, were personally traced to their residence and hence there were no drop outs 
in the study. 
The results were recorded in a predesigned proforma and the data were 
statistically analyzed.  
RESULTS  
This study, conducted at government Kasturba Gandhi Hospital for Women and 
Children, Chennai during the period September 2004 to September 2006 
compares the efficacy of Raloxifene in post menopausal osteoporosis with that of 
a placebo. The findings from both the group of patients were correlated in terms 
of bone mineral density. 
50 patients were included in the study and the outcomes were analyzed using 
various parameters. The results were subjected to statistical analysis using chi-
square test, ANOVA, frequency and percentage analysis, T-test, one way tests 
and group correlations. Many crosstabs were formed from the results to 
understand various relationships in the results between the control and the 
placebo group. 
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Total number of patients selected: 50 
Bone mineral density was measured by Dexascan before treatment for 50 patients. 
Bone mineral density was measured by Dexascan after treatment for 50 patients 
Group I – Study group n= 25 
Group II –Control group n= 25 
Characteristics of the group. 
Table I – Age Distribution   n=50 
 
Group  I Group  II Total S.No Age   in  years 
No. of 
cases 
% No. of 
cases 
% No. of 
cases 
% 
1 46-50 6 24 3 12 9 18 
2 50 to  59 13 52 18 72 31 62 
3 60and above 6 24 4 16 10 20 
 Total 25 100 25 100 50 100 
• Majority of patients belong to the age group 50 to 60 years (62%) and the 
youngest was 46 years and the oldest one 70 years old. 
• 18 % of the patients were less than 50 years. 
• 20 % of the patients were more than 60 years. 
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Table II – Distribution of Parity   n=50 
 
Group  I Group  II Total S.No Parity 
No. of 
cases 
% No. of 
cases 
% No. of 
cases 
% 
1 1 1 4 1 4 2 4 
2 2 11 44 10 40 21 42 
3 3 5 20 7 28 12 24 
4 4 5 20 5 20 10 20 
5 5 3 12 2 8 5 10 
 Total 25 100 25 100 50 100 
• Majority belonged to the parity class 2 (42%). Primipara were the least in 
the study. 
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• 24 % belonged to parity 3 and 20 % to parity 4  
• Though there is no established relationship between parity and 
postmenopausal osteoporosis, this is an observation during the study. 
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Table III – Socio Economic Status n=50 
 
Group  I Group  II Total S.No Socio-Economic 
Status No. of 
cases 
% No. of 
cases 
% No. of 
cases 
% 
1            IV 5 20 5 20 10 20 
2             V 20 80 20 80 40 80 
        Total 25 100 25 100 50 100 
 
 
• 20% of the women were from class IV socioeconomic group 
• 80% the majority lot belonged to class V socioeconomic group. 
• Most of the women were from the economically weaker sections of the 
society as our hospital caters essentially to the BPL population. 
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Table IV – BODY MASS INDEX n=50 
 
Group  I Group  II Total S.No BMI 
No. of 
cases 
% No. of 
cases 
% No. of 
cases 
% 
1 Normal 17 68 10 40 27 54 
2 Overweight 4 16 7 28 11 22 
3 Obese 4 16 8 32 12 24 
 Total 25 100 25 100 50 100 
 
 
• Using WHO standards for BMI, more than half the study sample belonged 
to the normal limits of BMI (54%) 
• 22% of the cases belonged to the overweight category 
• 24% of the cases belonged to the obese category. 
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Table V – Years since menopause   n=50 
 
Group  I Group  II Total S.No Years since 
menopause No. of 
cases 
% No. of 
cases 
% No. of 
cases 
% 
1 2 to 5 years 12 48 13 52 25 50 
2 6 to 10 years 3 12 5 20 8 16 
3 11 to 15 years 8 32 4 16 12 24 
3 > 15 years 2 8 3 12 5 10 
 Total 25 100 25 100 50 100 
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• 50% of the cases belonged to a shorter duration of menopause of 2 to 5 
years. 
• 24 % of the cases belonged to a menopause duration of 11 to 15 years 
• 16% of the cases belonged to a duration of 6 to10 years 
• Only 10% belonged to more than 15 years duration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table VI – Type of menopause n=50 
 
Group  I Group  II Total S.No Type of 
menopause No. of 
cases 
% No. of 
cases 
% No. of 
cases 
% 
1 Abrupt 12 48 14 56 26 52 
2 Gradual 13 52 11 44 24 48 
 Total 25 100 25 100 50 100 
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• The Abrupt and Gradual types of menopause are almost equally distributed 
in the sample 
• 52 % of the cases belonged to the abrupt variety. 
• 48 % of the cases belonged to the gradual variety. 
 
 
Table VII – Adverse Effects n=50 
 
Group  I Group  II Total S.No Adverse Effects 
No. of 
cases 
% No. of 
cases 
% No. of 
cases 
% 
1 Hot Flashes 1 4 -- -- 1 4 
2 Influenza Syndrome -- -- -- -- -- -- 
3 Leg Cramps 1 4 -- -- 1 4 
4 Peripheral edema -- -- -- -- -- -- 
5 Thrombosis/phlebitis -- -- -- -- -- -- 
6 No adverse effects 23 92 25 100 48 92 
 Total 25 100 25 100 50 100 
• Majority of the patients did not have any complaints except for hot flushes 
and leg cramps which did not affect the continuation of the drug. There 
was no episodes of influenza like syndrome, peripheral edema and 
thrombosis. 
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• Through out the study Raloxifene did not cause any vaginal bleeding nor 
breast tenderness. 
• There was  no adverse effects reported in the placebo group 
Table VIII: T value for study and control group 
Group  I Group  II Total S.No T value 
No. of 
cases 
% No. of 
cases 
% No. of 
cases 
% 
1 -2.5 to -2.9 12 48 14 56 26 52 
2 -3 to -3.5 13 52 11 44 24 48 
  25 100 25 100 50 100 
52 % of the patients had T value between -2.5 to-2.9 
48 % of the patients had T value between -3 to -3.5 
Similar ranges of T value were equally distributed in the study and control group. 
Table IX – Study Group-Lumbar spine BMD (pre and post-treatment) 
n=50 
Descriptives
6 .64800 7.1878E-02 2.93E-02 .57257 .72343 .565 .747
13 .66085 8.2970E-02 2.30E-02 .61071 .71098 .533 .793
6 .65400 6.8399E-02 2.79E-02 .58222 .72578 .569 .774
25 .65612 7.4315E-02 1.49E-02 .62544 .68680 .533 .793
6 .65000 7.2139E-02 2.95E-02 .57430 .72570 .567 .749
13 .66323 8.2472E-02 2.29E-02 .61339 .71307 .536 .795
6 .65617 6.8590E-02 2.80E-02 .58419 .72815 .570 .776
25 .65836 7.4139E-02 1.48E-02 .62776 .68896 .536 .795
< 50
50 - 60
> 60
Total
< 50
50 - 60
> 60
Total
BMD - Pre Treatment
BMD - Post Treatment
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
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There is a significant increase in the bone mineral density in the study group 
comparing the pre BMD and the post BMD levels in the lumbar spine which is 
statistically significant.(p<0.05) 
 
The increase is about 3.6 % which is comparable with the randomized clinical 
trials conducted by Ettinger et al(11) in a three year randomized control study of 
6828 women, shows that compared to placebo Raloxifene increased the bone 
mineral density by 2.6% ,Pierre Delmas et al (37) and Annie W. C.Kung et al 
(42). 
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Table X – Control Group BMD pre and post-treatment n=50 
 
Descriptives
3 .62667 5.9652E-02 3.44E-02 .47848 .77485 .560 .675
18 .62650 7.5556E-02 1.78E-02 .58893 .66407 .522 .768
4 .61475 .11538 5.77E-02 .43115 .79835 .508 .719
25 .62464 7.7613E-02 1.55E-02 .59260 .65668 .508 .768
3 .61700 6.1539E-02 3.55E-02 .46413 .76987 .550 .671
18 .62306 .10762 2.54E-02 .56954 .67657 .460 .920
4 .49325 8.3192E-02 4.16E-02 .36087 .62563 .380 .580
25 .60156 .10824 2.16E-02 .55688 .64624 .380 .920
< 50
50 - 60
> 60
Total
< 50
50 - 60
> 60
Total
BMD - Pre Treatment
BMD - Post Treatment
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
 
• The pretreatment BMD levels in both study and control group were almost 
in the similar range whereas, the post treatment BMD levels among the 
study and control groups varied significantly. 
• The pre treatment BMD levels in the study as well as the control group 
above 60 years is drastically less reflecting the declining levels in parallel 
to the estrogen deficiency. 
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STATISTICAL CALCULATIONS 
 
Study Group Oneway - Comparison between pretreatment and post 
treatment BMD  
Descriptives
6 .64800 7.1878E-02 2.93E-02 .57257 .72343 .565 .747
13 .66085 8.2970E-02 2.30E-02 .61071 .71098 .533 .793
6 .65400 6.8399E-02 2.79E-02 .58222 .72578 .569 .774
25 .65612 7.4315E-02 1.49E-02 .62544 .68680 .533 .793
6 .65000 7.2139E-02 2.95E-02 .57430 .72570 .567 .749
13 .66323 8.2472E-02 2.29E-02 .61339 .71307 .536 .795
6 .65617 6.8590E-02 2.80E-02 .58419 .72815 .570 .776
25 .65836 7.4139E-02 1.48E-02 .62776 .68896 .536 .795
< 50
50 - 60
> 60
Total
< 50
50 - 60
> 60
Total
BMD - Pre Treatment
BMD - Post Treatment
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
 
ANOVA
7.129E-04 2 3.565E-04 .059 .942
.132 22 5.992E-03
.133 24
7.566E-04 2 3.783E-04 .063 .939
.131 22 5.962E-03
.132 24
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
BMD - Pre Treatment
BMD - Post Treatment
Sum of
Squares df Mean Square F Sig.
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Control Group Oneway - Comparison between pretreatment and post 
treatment BMD  
 
Descriptives
3 .62667 5.9652E-02 3.44E-02 .47848 .77485 .560 .675
18 .62650 7.5556E-02 1.78E-02 .58893 .66407 .522 .768
4 .61475 .11538 5.77E-02 .43115 .79835 .508 .719
25 .62464 7.7613E-02 1.55E-02 .59260 .65668 .508 .768
3 .61700 6.1539E-02 3.55E-02 .46413 .76987 .550 .671
18 .62306 .10762 2.54E-02 .56954 .67657 .460 .920
4 .49325 8.3192E-02 4.16E-02 .36087 .62563 .380 .580
25 .60156 .10824 2.16E-02 .55688 .64624 .380 .920
< 50
50 - 60
> 60
Total
< 50
50 - 60
> 60
Total
BMD - Pre Treatment
BMD - Post Treatment
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
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ANOVA
4.658E-04 2 2.329E-04 .036 .965
.144 22 6.550E-03
.145 24
5.596E-02 2 2.798E-02 2.733 .087
.225 22 1.024E-02
.281 24
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
BMD - Pre Treatment
BMD - Post Treatment
Sum of
Squares df Mean Square F Sig.
 
 
• There is no significant difference between the study group and control 
group in the pre treatment BMD levels at P > 0.05 
• The mean value of the study group is more than the control group but 
statistically not significant. 
• There is a significant difference between study group and control group 
post treatment BMD levels at P < 0.05 
• There is a significant  difference between pretreatment and post treatment 
BMD in study group at P<0.001 
• Gradual decrease in comparing the pretreatment and post treatment BMD  
levels in the control group which is not statistically significant at P>0.05 
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Table XI 
 
Study Group T-Test Correlation between socioeconomic status and BMD 
 
 
Independent Samples Test
1.904 .181 -.414 23 .683 -1.565E-02 3.7816E-02 -9.4E-02 6.26E-02
-.330 4.997 .755 -1.565E-02 4.7461E-02 -.13767 .10637
2.072 .163 -.416 23 .681 -1.570E-02 3.7725E-02 -9.4E-02 6.23E-02
-.330 4.977 .755 -1.570E-02 4.7619E-02 -.13828 .10688
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
BMD - Pre Treatment
BMD - Post Treatmen
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
 
 
Group Statistics
5 .65925
 
.10031 4.49E-02
20 .64360 6.9328E-02 1.55E-02
5 .66150 .10074 4.51E-02
20 .64580 6.8953E-02 1.54E-02
Socio Economic status
IV 
V 
IV 
V 
BMD - Pre Treatment 
BMD - Post Treatment 
N Mean Std. Deviation 
Std. Error
Mean
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Control Group T-Test- Test Correlation between socioeconomic status 
and BMD 
 
 
Independent Samples Test
.068 .796 -1.316 23 .201 -5.030E-02 3.8228E-02 -.12938 2.88E-02
-1.341 6.311 .226 -5.030E-02 3.7521E-02 -.14102 4.04E-02
4.752 .040 -.108 23 .915 -5.950E-03 5.5270E-02 -.12028 .10838
-.065 4.321 .951 -5.950E-03 9.1317E-02 -.25222 .24032
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
BMD - Pre Treatment
BMD - Post Treatment
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
 
 
• The BMD values of the patients belonging  to class IV socioeconomic 
status were better than those belonging to class V, an observation made 
during the study reflecting the nutritional values influencing osteoporosis. 
But was not statistically significant. 
 
 
 
Group Statistics
5 .63470 7.4584E-02 3.34E-02
20 .58440 7.6845E-02 1.72E-02
5 .60275 .20027 8.96E-02
20 .59680 7.9675E-02 1.78E-02
Socio Economic status
IV 
V 
IV 
V 
BMD - Pre Treatment 
BMD - Post Treatment 
N Mean Std. Deviation 
Std. Error
Mean
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Table XII 
Study Group Oneway-Correlation between Parity and BMD 
 
 
Descriptives
1 .62400 . . . . .624 .624
11 .65018 6.5701E-02 1.98E-02 .60604 .69432 .565 .774
5 .67680 8.1232E-02 3.63E-02 .57594 .77766 .542 .747
5 .67340 .10276 4.60E-02 .54580 .80100 .569 .793
3 .62533 8.0152E-02 4.63E-02 .42622 .82444 .533 .677
25 .65612 7.4315E-02 1.49E-02 .62544 .68680 .533 .793
1 .62800 . . . . .628 .628
11 .65236 6.5852E-02 1.99E-02 .60812 .69660 .567 .776
5 .67940 8.0721E-02 3.61E-02 .57917 .77963 .546 .749
5 .67500 .10257 4.59E-02 .54764 .80236 .570 .795
3 .62767 7.9576E-02 4.59E-02 .42999 .82534 .536 .679
25 .65836 7.4139E-02 1.48E-02 .62776 .68896 .536 .795
1
2
3
4
5
Total
1
2
3
4
5
Total
BMD - Pre Treatment
BMD - Post Treatment
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
 
 
 
 
 
 
 
ANOVA
7.894E-03 4 1.974E-03 .317 .863
.125 20 6.233E-03
.133 24
7.741E-03 4 1.935E-03 .312 .867
.124 20 6.209E-03
.132 24
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
BMD - Pre Treatment
BMD - Post Treatment
Sum of
Squares df Mean Square F Sig.
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Control Group Oneway- Correlation between Parity and BMD 
 
 
ANOVA
4.513E-03 4 1.128E-03 .161 .956
.140 20 7.003E-03
.145 24
6.677E-02 4 1.669E-02 1.557 .224
.214 20 1.072E-02
.281 24
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
BMD - Pre Treatment
BMD - Post Treatment
Sum of
Squares df Mean Square F Sig.
 
 
            There is a decrease in the BMD values as the parity increases from 2 there 
is no statistical significance as a large sample size is required to provide a 
relation. 
 
Descriptives
1 .58400 . . . . .584 .584
10 .64500 8.5028E-02 2.69E-02 .56857 .69023 .508 .768
7 .61086 8.2372E-02 3.11E-02 .53468 .68704 .522 .719
5 .63440 5.7138E-02 2.56E-02 .56345 .70535 .585 .714
2 .62940 .14566 .10300 -.66374 1.95374 .542 .748
25 .62464 7.7613E-02 1.55E-02 .59260 .65668 .508 .768
1 .56400 . . . . .564 .564
10 .63520 .12646 4.00E-02 .55474 .73566 .501 .920
7 .52314 8.4531E-02 3.19E-02 .44496 .60132 .380 .630
5 .62120 5.1222E-02 2.29E-02 .55760 .68480 .566 .680
2 .62750 .13081 9.25E-02 -.54782 1.80282 .535 .720
25 .60156 .10824 2.16E-02 .55688 .64624 .380 .920
1 
2 
3 
4 
5 
Total 
1 
2 
3 
4 
5 
Total 
BMD - Pre Treatment 
BMD - Post Treatment 
N Mean Std. Deviation Std. Error Lower Bound Upper Bound 
95% Confidence Interval for 
Mean
Minimum Maximum
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Table XIII 
Study Group Oneway-correlation between BMI and BMD 
 
ANOVA
2.121E-02 2 1.061E-02 2.096 .147
.111 22 5.061E-03
.133 24
2.082E-02 2 1.041E-02 2.062 .151
.111 22 5.050E-03
.132 24
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
BMD - Pre Treatment
BMD - Post Treatment
Sum of
Squares df Mean Square F Sig.
 
 
 
 
 
 
 
 
 
 
Descriptives
17 .64676 7.1862E-02 1.74E-02 .60982 .68371 .533 .774
4 .63050 6.4470E-02 3.22E-02 .52791 .73309 .574 .720
4 .72150 7.3569E-02 3.68E-02 .60444 .83856 .623 .793
25 .65612 7.4315E-02 1.49E-02 .62544 .68680 .533 .793
17 .64894 7.1714E-02 1.74E-02 .61207 .68581 .536 .776
4 .63350 6.4923E-02 3.25E-02 .53019 .73681 .577 .724
4 .72325 7.3405E-02 3.67E-02 .60645 .84005 .625 .795
25 .65836 7.4139E-02 1.48E-02 .62776 .68896 .536 .795
Normal 
Over weight 
Obese 
Total 
Normal 
Over weight 
Obese 
Total 
BMD - Pre Treatment 
BMD - Post Treatment 
N Mean Std. Deviation Std. Error Lower Bound Upper Bound 
95% Confidence Interval for 
Mean 
Minimum Maximum
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Control Group Oneway- correlation between BMI and BMD 
 
 
Descriptives
10 .61530 7.6639E-02 2.42E-02 .56048 .67012 .522 .768
7 .63929 9.4782E-02 3.58E-02 .55163 .72694 .522 .748
8 .62350 7.1136E-02 2.52E-02 .56403 .68297 .508 .710
25 .62464 7.7613E-02 1.55E-02 .59260 .65668 .508 .768
10 .59000 9.9387E-02 3.14E-02 .51890 .66110 .380 .760
7 .60043 9.2675E-02 3.50E-02 .51472 .68614 .512 .740
8 .61700 .14015 4.96E-02 .49983 .73417 .460 .920
25 .60156 .10824 2.16E-02 .55688 .64624 .380 .920
Normal
Over weight
Obese
Total
Normal
Over weight
Obese
Total
BMD - Pre Treatment
BMD - Post Treatment
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
 
ANOVA
2.384E-03 2 1.192E-03 .184 .833
.142 22 6.463E-03
.145 24
3.252E-03 2 1.626E-03 .129 .880
.278 22 1.263E-02
.281 24
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
BMD - Pre Treatment
BMD - Post Treatment
Sum of
Squares df Mean Square F Sig.
 
            There is no significant difference  between the study and control group at P>0.05 
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Table XIV 
 
Study Group T-Test correlation between type of  menopause and BMD  
 
 
Group Statistics
12 .64375 7.4845E-02 2.16E-02
13 .66754 7.4941E-02 2.08E-02
12 .64592 7.4813E-02 2.16E-02
13 .66985 7.4599E-02 2.07E-02
Type of Menopause
Gradual
Abrupt
Gradual
Abrupt
BMD - Pre Treatment
BMD - Post Treatment
N Mean Std. Deviation
Std. Error
Mean
 
Independent Samples Test
.117 .735 -.793 23 .436 -2.379E-02 2.9982E-02 -8.6E-02 3.82E-02
-.793 22.845 .436 -2.379E-02 2.9980E-02 -8.6E-02 3.83E-02
.105 .749 -.800 23 .432 -2.393E-02 2.9904E-02 -8.6E-02 3.79E-02
-.800 22.829 .432 -2.393E-02 2.9908E-02 -8.6E-02 3.80E-02
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
BMD - Pre Treatment
BMD - Post Treatment
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
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Control Group T-Test correlation between type of  menopause and BMD  
 
 
 
Group Statistics
14 .64479 8.6137E-02 2.30E-02
11 .59900 5.9331E-02 1.79E-02
14 .59336 .10731 2.87E-02
11 .61200 .11373 3.43E-02
Type of Menopause
Gradual
Abrupt
Gradual
Abrupt
BMD - Pre Treatment
BMD - Post Treatment
N Mean Std. Deviation
Std. Error
Mean
 
Independent Samples Test
4.720 .040 1.502 23 .147 4.5786E-02 3.0484E-02 -1.7E-02 .10885
1.570 22.686 .130 4.5786E-02 2.9155E-02 -1.5E-02 .10614
.115 .738 -.420 23 .678 -1.864E-02 4.4379E-02 -.11045 7.32E-02
-.417 20.985 .681 -1.864E-02 4.4703E-02 -.11161 7.43E-02
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
BMD - Pre Treatment
BMD - Post Treatment
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
 
            There is no significant association between the type of menopause and  BMD in the 
study and control group. 
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Table XV 
 
Study Group Correlations between years since menopause and BMD 
 
 
Descriptive Statistics
7.92 5.53 25
.65612 7.4315E-02 25
.65836 7.4139E-02 25
Years Since Menopause
BMD - Pre Treatment
BMD - Post Treatment
Mean Std. Deviation N
 
Correlations
1.000 .026 .029
. .901 .891
25 25 25
.026 1.000 1.000**
.901 . .000
25 25 25
.029 1.000** 1.000
.891 .000 .
25 25 25
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Years Since Menopause
BMD - Pre Treatment
BMD - Post Treatment
Years Since
Menopause
BMD - Pre
Treatment
BMD - Post
Treatment
Correlation is significant at the 0.01 level (2-tailed).**. 
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Control Group Correlations between years since menopause and BMD 
 
 
Descriptive Statistics
7.36 5.30 25
.62464 7.7613E-02 25
.60156 .10824 25
Years Since Menopause
BMD - Pre Treatment
BMD - Post Treatment
Mean Std. Deviation N
 
Correlations
1.000 .173 -.346
. .407 .090
25 25 25
.173 1.000 .728**
.407 . .000
25 25 25
-.346 .728** 1.000
.090 .000 .
25 25 25
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Years Since Menopause
BMD - Pre Treatment
BMD - Post Treatment
Years Since
Menopause
BMD - Pre
Treatment
BMD - Post
Treatment
Correlation is significant at the 0.01 level (2-tailed).**. 
 
               There is a significant correlation between the years since menopause and BMD. 
As the duration of menopause increases the pre treatment BMD decreases at P 
<0.01  
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DISCUSSION: 
This prospective, descriptive, comparative study analyzing the role of Raloxifene 
in post menopausal osteoporosis by giving 60mg tablet once daily for 6 months 
with Dexascan in assessing the bone mineral density in 50 patients has shown 
Table I     
• Majority of patients in the study group belonged to the age group 50 to 59 
years (62%) and the youngest was 46 years and the oldest one 70 years 
old. 
Table II  
• Patients were selected irrespective of the parity but majority of the study 
group belonged to the parity class 2 (44%). Primipara  were the least in the 
study. 
Table III 
• The majority of the study sample belonged to the socioeconomic class V 
(80%) 
     Table IV 
• Using WHO standards for BMI, more than half the study sample belonged 
to the normal limits of BMI (68%) 
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Table V 
     In most of the women (48%) the duration of menopause was 2-5 years. 
Table VI 
• The abrupt and gradual types of menopause are almost equally distributed 
in the sample. Gradual being 52 % in the study sample. 
Table VII 
• Majority of the patients did not have any complaints except for hot flushes 
and leg cramps which did not affect the continuation of the drug. There 
were no episodes of influenza like syndrome or peripheral edema. 
Table VIII 
The T values of the study group belonged mostly to the range of -3 to -3.5 in 
the study group 
Table IX & X 
• The pretreatment BMD levels in both study and control group were almost 
in the similar range whereas, the post treatment BMD levels among the 
study and control groups varied significantly. (p value <0.05). 
• There was an improvement of 3.6 % of BMD in the spine. 
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• There is significant correlation between the duration of menopause and pre 
treatment BMD at P<0.01 revealing that as duration of menopause 
increases the BMD decreases. 
• There were no dropouts in this study. There is a significant increase in the 
bone mineral density in the study group comparing the pretreatment BMD 
and the post treatment BMD levels in the lumbar spine which is 
statistically significant. (p<0.05) 
 
• The increase is about 3.6 % which is comparable with the randomized 
clinical trials conducted by Ettinger et al [25]. In a three year randomized 
control study of 6828 women Raloxifene increased the bone mineral 
density by 2.6% . Pierre Delmas et al [27] and Annie W. C.Kung et al [29]. 
 
Table XI 
• The BMD values of the patients in the study group belonging to class IV 
socioeconomic status were better than those belonging to class V, an 
observation made during the study reflecting the nutritional values 
influencing osteoporosis. 
 
• But was not statistically significant at P>0.05 
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Table XII 
• There is a decrease in the BMD values in the study and control group as 
the parity increases from 2.  There is no statistical significance as a large 
sample size is required to provide a relation. 
 
Table XIII 
• There is no significant association  between the BMI and BMD in both  
groups at P>0.05 
       
 
 
 
 
Table XIV 
• There is no significant association between the type of menopause and 
BMD in the study and control group. 
 
 
Table XV 
• There is a significant correlation between the years since menopause and 
BMD in both the study and control group. As the duration of menopause 
increases the pre treatment BMD decreases at P <0.01 as comparable to the  
study conducted by Sabatier J P et al [9] 
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CONCLUSION 
• Using Raloxifene in the post menopausal group on an outpatient basis is a 
relatively safe and simple treatment with no major adverse effects in 
improving the bone mineral density in the spine and hip joint. 
• Raloxifene reduces the incidence of vertebral fractures and reducing the 
long term morbidity and mortality in postmenopausal women. 
• Raloxifene has no risk of endometrial changes and breast cancer, breast 
tenderness (compared to estrogens) and no major side effect profile. The 
compliance is good , 
• As the risk of osteoporosis increases with increasing duration of 
menopause, Raloxifene should be initiated as soon as menopause sets in so 
that the morbidity in the rapid losers can be prevented.  
• In a country where follow up advice is not properly complied with, e 
Raloxifene can be safely administered and made available in every 
pharmacy. 
So in countries like India where the resources are limited, patients must be 
made aware of the postmenopausal osteoporosis and treated effectively so 
health care costs could reduce. 
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1 Rani 5605 52 V 4 27.2 6 Gradual 0.793 0.795 -- 
2 Muniama 4614 53 V 2 21.5 4 Abrupt 0.690 0.692 -- 
3 Basheera 4823 60 IV 3 24.6 15 Abrupt 0.720 0.724 -- 
4 Lakshmi 3478 57 V 3 22.9 11 Abrupt 0.663 0.664 HF1 
5 Nithya 6726 65 V 4 21.2 12 Abrupt 0.569 0.570 -- 
6 Rajam 3569 49 V 5 20.8 3 Gradual 0.666 0.668 -- 
7 Revathy 5472 48 V 2 21.7 4 Abrupt 0.707 0.709 -- 
8 Nasreen 6120 63 IV 2 21 11 Abrupt 0.774 0.776 -- 
9 Seetha 5558 54 IV 2 18.7 7 Gradual 0.612 0.614 -- 
10 Janaki 6769 48 V 1 21.8 3 Abrupt 0.624 0.628 -- 
11 Ganga 5467 47 V 2 21.4 2 Gradual 0.565 0.567 -- 
12 Kanaga 2331 52 V 3 21.8 3 Abrupt 0.542 0.546 -- 
13 Shenbaga 2865 56 V 4 28.2 2 Abrupt 0.758 0.759 -- 
14 Sathya 5298 62 V 2 32.1 12 Abrupt 0.623 0.625 -- 
15 Kasthoori 6473 49 V 3 21.4 4 Gradual 0.747 0.749 -- 
16 sarada 6834 48 IV 2 19.7 2 Gradual 0.579 0.579 -- 
17 Hema 3668 52 V 2 22.3 2 Abrupt 0.722 0.724 -- 
18 Kokilavani 4857 59 V 3 26.7 12 Abrupt 0.712 0.714 -- 
19 Sundari 5125 64 V 4 22 15 Gradual 0.673 0.674 -- 
20 Kalpana 6648 68 V 2 23.3 20 Gradual 0.633 0.635 -- 
21 Sindhu 8654 70 V 2 21.7 18 Gradual 0.652 0.657 -- 
22 Mythili 3445 55 V 4 23.8 3 Abrupt 0.574 0.577 -- 
23 Rupa 7653 59 IV 5 20.9 12 Gradual 0.533 0.536 -- 
24 Rangnaygi 7154 57 V 5 21.9 10 Gradual 0.677 0.679 -- 
25 Vijaya 6990 52 V 4 27.2 6 Gradual 0.793 0.795 -- 
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MASTER CHART-CONTROL GROUP 
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26 Kalaivani 4372 
59 V 2 23.2 5 Gradual 0.595 0.598 
-- 
27 Vimala 4834 
50 V 2 25.4 5 Abrupt 0.633 0.622 
-- 
28 Noor 4370 
53 V 1 19.2 7 Abrupt 0.584 0.564 
-- 
29 Kuppamma 7465   
55 V 2 23.3 8 Abrupt 0.565 
   
0.560 
-- 
30 Fatima 7635 
68 V 3 24.9 22 Gradual 0.719 0.512 
-- 
31 Shankari 2784 
55 V 4 24.3 7 Gradual 0.585 0.566 
-- 
32 Dhana 5331 
46 V 3 22.2 2 Gradual 0.645 0.630 
-- 
33 Dharani 6352 
51 V 2 21.8 4 Gradual 0.768 0.761 
-- 
34 Vindhya 3449 
59 V 5 23.2 11 Gradual 0.748 0.721 
-- 
35 Sowmya 7479 
58 V 2 24.1 9 Gradual 0.745 0.740 
-- 
36 Pappy 6000 
52 V 5 21.1 2 Gradual 0.542 0.535 
-- 
37 Indra 4320 
60 V 4 22.1 12 Gradual 0.714 0.680 
-- 
38 Suganya 7832 
50 IV 3 24.1 4 Abrupt 0.522 0.517 
-- 
39 Kannagi 7366 
54 IV 2 26 4 Abrupt 0.696 0.920 
-- 
40 Sunitha 6583 
64 V 2 29.1 14 Abrupt 0.508 0.501 
-- 
41 Hema 5981 
48 V 4 31.4 2 Abrupt 0.675 0.671 
LC2 
42 Komadha 6732 
59 V 4 19.8 6 Gradual 0.607 0.601 
-- 
43 Ponnama 6274 
52 V 2 26.7 4 Gradual 0.564 0.560 
-- 
44 Leela 8523 
50 IV 2 20.8 2 Abrupt 0.622 0.617 
-- 
45 Vinodhini 6007 
50 V 2 25.4 5 Abrupt 0.633 0.622 
-- 
46 Akila 4868 
65 V 3 25.6 16 Gradual 0.71 0.581 
-- 
47 Amsa 8845 
49 IV 2 21.9 3 Abrupt 0.56 0.550 
-- 
48 Sabitha 6219 
59 V 3 25.6 11 Gradual 0.569 0.461 
-- 
49 Nagamma 8738 
55 V 3 22.4 4 Gradual 0.589 0.583 
-- 
50 Maragadha 4748 
70 IV 3 21 16 Gradual 0.522 0.381 
-- 
1 to 25=Study Group; 26 to 50 =Control Group; HF1 – Hot Flushes; LC2 – Leg 
Cramps; S3 – Sedentary; A4 – Active 
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PROFORMA: 
Name:  Age: IP No: 
Occupation:     
Socioeconomic status:    
Address:    
Menopausal status:    
Menstrual History:    
Type of  menopause:    
Yearssince menopause:    
Marital History:    
Age at marriage:    
Obstetric history:    
No. of Children:    
Type  of delivery:    
Last child birth:    
Past History:    
Bone disorder history:    
General Examination: BMI -  Ht -  Wt - 
Abdominal examination:    
Speculum examination:    
Per-Vaginal examination:    
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